RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis

Related Experiment Video

Updated: Sep 19, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Junmei Zhang1, Shuai Wang2, Tingting Li3

  • 1Department of Dermatology, Northern Theater Command General Hospital, Shenyang, Liaoning, China.

Journal of the National Cancer Institute
|June 6, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Related Experiment Videos

Last Updated: Sep 19, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Career Compromise, Perceived Organizational Support, and Professional Identity in Nurses: A Latent Profile Analysis and Mediation Study.

Journal of nursing management·2026

Case report: Systemic T-DXd and bevacizumab plus local therapy prolongs survival in breast cancer leptomeningeal metastasis: a case series and literature review.

Frontiers in oncology·2026

Hinge-region Cys-to-Ser mutation enables homogeneous DAR6 anti-c-Met biparatopic ADCs with tolerable O-glycosylation.

Antibody therapeutics·2026

Clinical Features and a Nomogram for Predicting Clinical Response in Juvenile Dermatomyositis-Associated Interstitial Lung Disease.

The Journal of rheumatology·2026

The hypoxic burden algorithm: an integrated index for assessing intermittent hypoxia in pediatric obstructive sleep apnea-a retrospective cohort study.

Translational pediatrics·2026

Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy.

Cell reports. Medicine·2026

Caregivers and legal barriers: navigating care of a family member diagnosed with cancer.

Journal of the National Cancer Institute·2026

Subgroup variations in benefit from telehealth palliative care for advanced lung cancer.

Journal of the National Cancer Institute·2026

Statewide surveillance of colorectal cancer screening using geospatial and Multi-Payer claims data.

Journal of the National Cancer Institute·2026

Head and neck cancer in older adults: biological aging, treatment tolerance, and survivorship.

Journal of the National Cancer Institute·2026

Employment after curative breast cancer treatment: the breast cancer and the workforce cohort study.

Journal of the National Cancer Institute·2026

Modeling the survival impact of the Inflation Reduction Act out-of-pocket cap in multiple myeloma.

Journal of the National Cancer Institute·2026

Testosterone treatment prevents most gonadectomy-induced metabolic and skeletal deficiencies in female mice.

Frontiers in endocrinology·2026

Metabolic oncology: clonal selection and the pre-existing origins of cancer resistance.

Frontiers in oncology·2026

Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis.

Frontiers in oncology·2026

Rutin interferes with hnRNP L phase separation and modulates the PKM2-lactate-H3K9la axis in pulmonary fibrosis.

Frontiers in pharmacology·2026

PROTAC-DB 4.0: an expanded knowledgebase of targeted protein degradation modalities with AI-powered knowledge discovery.

Nucleic acids research·2026

Single-Nucleus Transcriptomics Reveal Mechanisms of Cardiovascular Protection Against Ponatinib-Induced Cardiotoxicity Through ROCKs Deletion in Cardiomyocytes.

Archivum immunologiae et therapiae experimentalis·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us